CCL4L2 and central nervous system cancer: Others were robust and shared across most samples such as CD74 receptor binding to MIF, COPA, or APP as cognate ligands and SPP1-CD44 (myeloid to glioma signaling) and TNFRSF1A-GRN, PGRMC2-CCL4L2, MDK-SORL1 or LRP1, and GPR37L1-PSAP (glioma to myeloid signaling).